查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1860352

凝血因子市場依產品類型、適應症、製劑形式、最終用戶、通路和給藥途徑分類－全球預測（2025-2032 年）

Coagulation Factor Concentrates Market by Product Type, Indication, Formulation, End User, Distribution Channel, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，凝血因子濃縮物市場規模將達到 171.4 億美元，複合年成長率為 8.62%。

關鍵市場統計數據
基準年 2024 88.4億美元
預計年份：2025年 95.9億美元
預測年份 2032 171.4億美元
複合年成長率 (%) 8.62%

清楚展現凝血因子濃縮物市場格局的演變，將治療創新、臨床應用、監管預期和供應穩定性連結起來。

凝血因子濃縮物市場正處於先進生物製藥生產技術、不斷發展的臨床通訊協定和日益嚴格的供應鏈監管三者交匯點。本文回顧了影響包括醫院、專科護理中心和分銷合作夥伴在內的相關人員決策的治療、營運和商業因素。文章強調了可靠的產品供應對於出血性疾病患者的重要性，並指出凝血因子濃縮物對於按需治療和預防性治療都至關重要。

隨著傳統血漿衍生產品向重組工程產品的轉變，臨床醫師和採購團隊在選擇治療方案時，會全面評估療效、安全性、給藥頻率和總治療成本。同時，監管機構的期望和支付方的評估也越來越關注真實世界的臨床結果、療效比較和藥物經濟學證據。長效生物製藥的創新與持續存在的血漿供應限制和生產複雜性之間的相互作用，既給生產者、醫療服務提供者和政策相關人員帶來了機遇，也帶來了挑戰。

在後續的每個章節中，本引言為深入分析奠定了基礎，重點介紹了關鍵的治療類別和臨床環境，並為將臨床實踐與強大的商業策略相結合的實用建議奠定了基礎。

科學突破、不斷發展的護理模式和供應鏈改進將如何重塑凝血因子濃縮物的治療選擇和商業策略

凝血因子濃縮物領域正經歷一系列變革，這些變革的驅動力包括科學進步、醫療模式的轉變以及對供應鏈完整性的日益重視。重組技術和製劑研發的進步使得給藥間隔得以延長，輸注負擔得以減輕，這促使臨床醫生重新評估預防性給藥方案，並鼓勵患者在關注療效指標的同時，也考慮生活品質的改善。同時，基因療法和非因子療法的出現，引入了新的臨床終點和患者分層標準，這將影響長期的需求模式和治療流程。

在營運方面，製造商正加大對生物製藥產能、製程穩健性和低溫運輸物流的投資，以滿足日益成長的品質和可追溯性要求。支付者和醫療系統要求獲得更強力的真實世界數據和更清晰的價值評估，這促使臨床相關人員和行業之間開展更緊密的合作，以產生療效數據並最佳化治療路徑。此外，數位健康工具和遠端醫療正在改變病患監測和用藥支持的方式，有助於更積極主動地管理出血事件，並將治療融入患者的日常生活。

鑑於這些變化，企業和醫療保健提供者需要平衡短期准入需求與長期創新策略，以確保治療進步轉化為永續的臨床和商業性價值。

預測計劃於 2025 年進行的關稅調整對採購、製造業採購和合約模式的連鎖反應，這些反應將影響市場准入和成本動態。

美國計劃於2025年實施的政策變化和關稅調整，為製造商和醫療保健採購商帶來了新的成本動態和採購考量。關稅導致的投入成本上升可能會對上游供應鏈造成壓力，尤其是那些依賴跨境採購特殊試劑、一次性技術或輔助包裝組件的生產商。為此，製造商正在評估近岸外包、雙重採購策略以及合約保護措施，以維持利潤彈性和供應連續性。

醫療系統和專科藥局正在調整採購流程和庫存管理政策，以應對價格波動並保障病患用藥。因此，合約模式正朝著與指數掛鉤的定價機制和更高的服務水準保障的長期協議方向發展。藥物治療委員會越來越重視醫療保健總成本，以及長效和標準半衰期療法在給藥頻率和資源利用方面的可比較性。

此外，關稅的影響凸顯了監管協調以及與海關和貿易當局積極合作以最大限度減少干擾的重要性。臨床團隊正日益與供應鏈領導者合作，以確保治療藥物的供應，同時推進成本控制措施，確保關稅調整不會導致患者療效下降。

對治療方案、臨床工作流程和分銷策略的細分影響（按產品類型、適應症、劑型和臨床環境分類）

了解這種細分方式的細微差別，有助於闡明不同產品、適應症、劑型、最終用戶、通路和給藥途徑在治療開發、臨床應用和分銷重點方面的差異。產品類型之間的差異主要體現在血漿衍生濃縮物和重組產品上，後者可進一步細分為長效和標準半衰期版本。這種結構上的二分法會影響生產複雜性、藥物動力學以及在預防保健中的定位。

不同的適應症等級至關重要，血友病A、血友病B和血管性血友病的治療強度和監測方式各不相同。對於血友病A和B，輕度、中度或重度分類會影響預防性治療的啟動、給藥頻率和緊急使用。血管性血友病有其自身的臨床亞型（I、II和III型），這些亞型會影響治療策略和凝血因子濃縮劑的選擇。製劑形式的選擇（液體或冷凍乾燥粉）會影響保存期限、低溫運輸需求和床邊配製程序，進而影響醫院藥局的工作流程和專科治療中心的管理。

終端使用者趨勢集中在醫院和專科護理中心，這些機構的輸液基礎設施、多學科團隊和急診系統能夠支援複雜的個案管理。通路包括醫院藥房、線上藥房和零售藥房，每個管道的存貨周轉、報銷途徑和患者取藥方式各不相同。最後，靜脈注射仍然是主要的給藥途徑，這決定了輸液訓練、血管通路規劃和護理工作量。了解這些相互關聯的環節有助於制定更個人化的臨床通訊協定、更有針對性的商業性策略和更最佳化的供應鏈。

區域監管環境、血漿供應韌性和商業模式如何導致美洲、歐洲、中東和非洲以及亞太地區血漿取得途徑的差異

區域趨勢將對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、監管時間表和供應鏈設計產生不同的影響。在美洲，高度集中的血友病專科治療中心和完善的報銷機制支持了先進重組療法的快速應用。然而，該地區也面臨支付方准入政策的差異以及生技藥品低溫運輸物流環境的複雜性。

在歐洲、中東和非洲地區，跨司法管轄區的監管協調和集中採購機制既為規模化生產提供了機遇，也帶來了各國報銷制度差異帶來的挑戰。製造商必須應對不同的競標流程，並根據不同的衛生技術評估 (HTA) 框架調整證據材料。亞太地區的市場環境複雜多樣，有些市場應用迅速，而有些市場的治療基礎設施尚不成熟。製造商通常會採取分階段的商業化策略，以適應當地不同的生產夥伴關係關係、血漿採集能力和支付方的準備。

無論在哪個地區，血漿供應、當地生產能力和監管溝通策略都將決定市場前置作業時間和商業性准入。因此，相關人員應根據當地實際情況調整分銷模式、臨床證據產生和相關人員拓展策略，同時保持全球品質標準和可追溯性。

競爭優勢源自於製造技術專長、重組創新、策略合作夥伴關係以及決定市場進入和臨床應用的真實世界臨床結果。

凝血因子濃縮劑市場的競爭動態由現有血漿衍生製劑生產商、重組生物製藥以及專注於延長半衰期結構和替代療法的新興創新者共同塑造。現有生產商憑藉其在血漿分餾技術、供體網路和大規模生產方面的深厚專業知識，而重組製劑生產商則透過分子工程、延長給藥間隔和簡化給藥方案來提高預防性治療的依從性。

合作關係和策略聯盟持續影響企業的競爭定位，生物製藥公司與專科藥房和醫院網路合作，加速病患用藥計畫和實證醫學證據的累積。同時，新參與企業則著重於針對罕見亞型（例如特定嚴重程度的患者群體或特定血管性血友病表現型）的細分市場定位，以建立臨床信譽並獲得支付方的支持。生產規模、監管記錄以及展現可靠的真實世界療效的能力，正日益成為醫療系統評估治療方案時的決定性因素。

因此，商業領袖必須平衡對新型治療方案的投資與供應鏈連續性和監管合規性的卓越營運，以保持競爭優勢並支持以患者為中心的長期照護模式。

製造商和供應商可採取切實可行的策略步驟，以增強供應韌性、加速重組產品應用，並使臨床結果與支付方價值一致。

產業領導者可以透過一系列有針對性且切實可行的措施來增強自身韌性和競爭優勢。首先，他們可以實現籌資策略多元化，投資本地製造和委託製造夥伴關係關係，以降低跨境關稅波動風險，並縮短關鍵材料的前置作業時間。同時，他們可以增加對長效重組平台的投資，這些平台能夠減少輸注頻率並提高用藥依從性，從而累積衛生經濟學證據，凸顯其在降低整體醫療成本方面的益處。

同時，我們將與支付方和臨床相關人員深入合作，共同設計結果研究和註冊登記，以按疾病嚴重程度分層和血管性血友病亞型評估真實世界的療效。我們將透過擴大對專科藥房和線上藥房管道的支持，增強分銷靈活性，同時與醫院的急性給藥通訊協定保持緊密一致。在營運方面，我們將加強低溫運輸管理、批次追溯和緊急庫存通訊協定，以減輕供應中斷的影響。

最後，我們優先發展以患者為中心的服務，例如輸液教育、依從性技術和居家照護支持，以改善長期療效並在商業性脫穎而出。這些努力將共同帶來臨床效益、商業性永續性和組織韌性。

為了確保分析的嚴謹性，我們採用了穩健的混合調查方法，結合了臨床醫生訪談、監管證據綜合和交叉檢驗的二手資料。

本分析所依據的研究採用了混合方法，結合了定性訪談、有針對性的二手研究以及監管和臨床文獻的綜合分析，從而構建了該領域的多維度視角。研究人員透過與血液科醫生、藥屋主任、供應鏈經理和支付方進行結構化訪談，收集了關鍵見解，以檢驗臨床實踐模式、採購趨勢和准入限制。這些訪談內容被用來建構情境並評估對關稅敏感的供應流。

本研究利用了包括同行評審的臨床研究、監管核准和指導文件、產品標籤以及上市公司披露資訊二級資訊來源，對產品特性、安全性概況和給藥方案進行三角驗證。在分析過程中，我們檢驗一手和二手資訊來源進行了嚴格的交叉檢驗，以確保資訊的一致性並識別出需要進一步調查的差異。必要時，我們會對方法進行調整，以考慮區域監管差異以及綜合醫院和專科護理中心之間給藥模式的差異。

整個過程中都融入了數據品質檢查和專家審查環節，以增強結論的可信度，並確保實際建議能夠反映臨床實際情況和操作限制。

制定全面的策略重點，將創新技術、供應連續性和支付方合作結合，以確保醫療服務的持續可及性和改善患者療效。

總之，凝血因子濃縮物處於臨床需求與技術進步的策略交會點。重組技術、長效製劑和不斷發展的護理模式為改善患者預後和減輕輸血負擔提供了重要機會。然而，血漿供應、生產複雜性和支付方監管等持續存在的挑戰限制了近期實施的風險。法規結構和分銷基礎設施的區域差異進一步增加了商業化策略的複雜性，因此需要採取區域性策略。

為取得成功，相關人員必須將創新研發管線與供應鏈連續性和實證醫學的營運投資結合。透過整合以患者為中心的服務、積極主動地與支付方溝通以及製定穩健的籌資策略，製造商和醫療服務提供者可以在不影響患者可及性的前提下，提供可衡量的臨床獲益。本執行摘要中的建議為將科學進步轉化為永續的臨床和商業性成果提供了路線圖，從而確保出血性疾病患者能夠及時獲得有效的藍圖。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大使用長效VIII因子和IX因子產品，以減少給藥頻率並提高患者依從性
  • 增加A型血友病基因治療試驗的投資，以期提供一次根治性此病的難得機會。
  • 生物相似因子VIII和因子IX濃縮製劑的出現，在定價和市場進入方面對現有品牌產品構成了挑戰。
  • 透過整合基於藥物動力學的個人化給藥平台最佳化凝血因子濃縮物預防方案
  • 開發皮下注射和非靜脈注射凝血因子濃縮劑，以提高患者的便利性和生活品質
  • 擴大血漿採集網路和數位化供應鏈解決方案，以緩解全球原料短缺問題。
  • 利用真實世界數據和註冊數據，證明新型凝血療法的長期安全性和有效性。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 凝血因子市場（依產品類型分類）

  • 血漿衍生
  • 重組製劑
    • 延長半衰期
    • 標準半衰期

9. 依適應症分類的凝血因子市場

  • A型血友病A
    • 溫和的
    • 緩和
    • 嚴重
  • B型血友病
    • 溫和的
    • 緩和
    • 嚴重
  • 血管性血友病
    • 一型
    • II 型
    • III型

10. 凝血因子製劑市場（依產品分類）

  • 液體
  • 凍乾粉

第11章 依最終使用者分類的凝血因子市場

  • 醫院
  • 專業醫療機構

12. 凝血因子市場依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

13. 依給藥途徑分類的凝血因子市場

  • 靜脈注射

14. 各地區凝血因子市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 凝血因子市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國凝血因子市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • CSL Limited
    • Grifols, SA
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Novo Nordisk A/S
    • Sanofi SA
    • Bayer Aktiengesellschaft
    • LFB SA
    • Kedrion SpA
Product Code: MRR-DD0700E81E59

The Coagulation Factor Concentrates Market is projected to grow by USD 17.14 billion at a CAGR of 8.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.84 billion
Estimated Year [2025] USD 9.59 billion
Forecast Year [2032] USD 17.14 billion
CAGR (%) 8.62%

A clear framing of the evolving coagulation factor concentrates landscape linking therapeutic innovation, clinical delivery, regulatory expectations, and supply resilience

The landscape of coagulation factor concentrates stands at the intersection of advanced biologics manufacturing, evolving clinical protocols, and intensified supply chain scrutiny. This introduction frames the therapeutic, operational, and commercial dimensions that shape stakeholder decisions across hospitals, specialty treatment centers, and distribution partners. It highlights the criticality of reliable product availability for patients living with bleeding disorders and positions concentrates as indispensable in both on-demand and prophylactic care pathways.

Transitioning from traditional plasma-derived products toward engineered recombinant options, clinicians and procurement teams now weigh efficacy, safety, dosing frequency, and total cost of care when selecting therapies. Concurrently, regulatory expectations and payer assessments increasingly emphasize real-world outcomes, comparative effectiveness, and pharmacoeconomic evidence. The interplay between innovation in extended half-life biologics and the persistent constraints of plasma supply and manufacturing complexity creates both opportunities and pressures for manufacturers, healthcare providers, and policy stakeholders.

In the sections that follow, this introduction provides a foundation for deep-dive analysis, clarifies the principal therapeutic categories and care settings, and sets the stage for actionable recommendations that align clinical practice with resilient commercial strategies.

How scientific breakthroughs, evolving care paradigms, and supply chain reinforcement are reshaping therapeutic choices and commercial strategies in coagulation concentrates

The coagulation factor concentrates sector is undergoing a set of transformative shifts driven by scientific advances, changing care models, and intensified attention to supply chain integrity. Recombinant engineering and formulation work continue to extend dosing intervals and reduce infusion burdens, prompting clinicians to reassess prophylactic regimens and patients to consider quality-of-life benefits alongside efficacy metrics. At the same time, gene therapies and non-factor modalities introduce new clinical endpoints and patient stratification criteria that will influence long-term demand patterns and treatment algorithms.

On the operational side, manufacturers are investing in biologics capacity, process robustness, and cold-chain logistics to meet heightened quality and traceability expectations. Payers and health systems demand stronger real-world evidence and value articulation, which has prompted closer collaboration between clinical stakeholders and industry to generate outcomes data and optimize care pathways. Additionally, digital health tools and telemedicine are reshaping patient monitoring and adherence support, enabling more proactive management of bleeding episodes and better integration of treatment within patients' daily lives.

Taken together, these shifts require companies and providers to balance near-term access imperatives with longer-term innovation strategies, ensuring that therapeutic advances translate into sustainable clinical and commercial value.

Anticipating the ripple effects of 2025 tariff adjustments across procurement, manufacturing sourcing, and contracting arrangements that influence access and cost dynamics

Policy changes and tariff adjustments in the United States slated for 2025 have introduced new cost dynamics and sourcing considerations for manufacturers and healthcare purchasers. Tariff-driven input cost increases can create pressure points along the upstream supply chain, particularly for producers that depend on cross-border procurement of specialized reagents, single-use technologies, or ancillary packaging components. In response, manufacturers are evaluating nearshoring, dual-sourcing strategies, and contractual protections to preserve margin resilience and continuity of supply.

Health systems and specialty pharmacies are adjusting procurement workflows and inventory policies to manage price volatility and to maintain patient access. As a consequence, contracting models are evolving toward longer-term agreements with indexed pricing mechanisms and enhanced service-level commitments. Pharmacy and therapeutics committees are placing greater emphasis on total cost of care and on the comparability of dosing frequency and resource utilization between extended half-life and standard half-life therapies.

Moreover, tariff implications amplify the importance of regulatory harmonization and of proactive engagement with customs and trade authorities to minimize disruption. Clinical teams are collaborating more closely with supply chain directors to preserve therapeutic availability while navigating cost containment, thereby ensuring that tariff-driven adjustments do not translate into compromised patient outcomes.

Segment-driven implications for therapeutic selection, clinical workflows, and distribution strategies across product types, indications, formulations, and care settings

A nuanced understanding of segmentation clarifies how therapeutic development, clinical adoption, and distribution priorities differ across product, indication, formulation, end user, distribution channel, and administration route. Product-type distinctions center on plasma-derived concentrates and recombinant products, with recombinant offerings further differentiated between extended half-life and standard half-life constructs; this structural dichotomy influences manufacturing complexity, pharmacokinetics, and positioning in prophylactic care.

Indication-level nuances matter because treatment intensity and monitoring differ across Hemophilia A, Hemophilia B, and Von Willebrand Disease. Within Hemophilia A and Hemophilia B, stratification into mild, moderate, and severe categories drives considerations around prophylaxis initiation, dosing frequency, and emergency use. Von Willebrand Disease presents its own clinical subtypes-Type I, Type II, and Type III-that shape therapeutic preferences and factor concentrate selection. Formulation choices, whether liquid presentations or lyophilized powders, affect shelf life, cold-chain requirements, and bedside preparation protocols, which in turn influence hospital pharmacy workflows and specialty center administration.

End-user dynamics are concentrated in hospitals and specialty centers where infusion infrastructure, multidisciplinary teams, and acute care capabilities enable complex case management. Distribution channels vary between hospital pharmacies, online pharmacies, and retail pharmacies; each channel brings different inventory turn rates, reimbursement pathways, and patient access mechanisms. Finally, the predominant route of administration remains intravenous, which dictates infusion training, vascular access planning, and nursing workload. Understanding these intersecting segments enables more tailored clinical protocols, targeted commercial approaches, and optimized supply arrangements.

How regional regulatory landscapes, plasma supply resilience, and commercial models shape access pathways differently across the Americas, EMEA, and Asia-Pacific

Regional dynamics influence clinical practice, regulatory timelines, and supply chain design in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, concentrated pockets of specialized hemophilia treatment centers and established reimbursement pathways support rapid adoption of advanced recombinant therapies, while the region also contends with disparities in payer access policies and a complex logistics environment for cold-chain biologics.

In Europe, Middle East & Africa, regulatory harmonization across jurisdictions and centralized procurement mechanisms can create both opportunities for scale and challenges related to country-level reimbursement heterogeneity. Manufacturers must navigate divergent tender processes and align evidence packages to satisfy multiple HTA frameworks. The Asia-Pacific region presents a heterogenous environment where rapid uptake in some markets coexists with nascent treatment infrastructures in others; manufacturers often pursue phased commercialization strategies that reflect local manufacturing partnerships, plasma collection capacities, and evolving payer readiness.

Across regions, resilience of plasma supply, local manufacturing capabilities, and regulatory engagement strategies will determine lead times and the shape of commercial access. Stakeholders should therefore tailor distribution models, clinical evidence generation, and stakeholder outreach to regional specificities while maintaining global quality and traceability standards.

Competitive positioning driven by manufacturing expertise, recombinant innovation, strategic partnerships, and real-world outcomes that determine access and clinical adoption

Competitive dynamics in the coagulation factor concentrates arena are shaped by incumbent plasma-derived manufacturers, recombinant biologics producers, and emerging innovators focused on extended half-life constructs and alternative modalities. Established producers leverage deep expertise in plasma fractionation, donor networks, and large-scale manufacturing, while recombinant players differentiate through molecular engineering, longer dosing intervals, and simplified administration profiles that support prophylaxis adherence.

Partnerships and strategic alliances continue to define competitive positioning, with collaborations between biopharma firms and specialty pharmacies or hospital networks accelerating patient access programs and evidence generation. At the same time, newcomers emphasize niche positioning-targeting specific severity cohorts or rare subtypes such as particular Von Willebrand disease presentations-to build clinical credibility and payer momentum. Manufacturing scale, regulatory track record, and the ability to demonstrate robust real-world outcomes are increasingly decisive factors when health systems evaluate therapeutic options.

Consequently, commercial leaders must balance investment in novel therapeutic profiles with operational excellence in supply continuity and regulatory compliance to maintain competitive advantage and to support long-term patient-centric care models.

Practical strategic measures for manufacturers and providers to fortify supply resilience, accelerate recombinant adoption, and align clinical outcomes with payer value

Industry leaders can strengthen resilience and competitive positioning through a set of targeted, actionable initiatives. First, diversify sourcing strategies and invest in regional manufacturing or tolling partnerships to reduce exposure to cross-border tariff fluctuations and to shorten lead times for critical inputs. Simultaneously, ramp up investment in extended half-life recombinant platforms that demonstrably reduce infusion frequency and improve adherence, while also building the health economic case that highlights total cost of care improvements.

In parallel, deepen engagement with payers and clinical stakeholders by co-designing outcomes studies and registries that capture real-world effectiveness across severity strata and Von Willebrand disease subtypes. Strengthen distribution flexibility by expanding support for specialty and online pharmacy channels while preserving tight integration with hospital pharmacy protocols for acute administration. Operationally, enhance cold-chain oversight, batch traceability, and emergency stock protocols to mitigate the impact of supply disruptions.

Finally, prioritize patient-centric services-such as infusion education, adherence technologies, and homecare enablement-to improve long-term outcomes and to differentiate commercially. Taken together, these measures align clinical benefits with commercial sustainability and organizational resilience.

A robust mixed-method research approach integrating clinician interviews, regulatory evidence synthesis, and cross-validated secondary sources to ensure analytical rigor

The research underpinning this analysis deployed a mixed-method methodology that combined qualitative interviews, targeted secondary research, and synthesis of regulatory and clinical literature to create a multi-dimensional view of the sector. Primary insights were gathered through structured interviews with hematologists, pharmacy directors, supply chain leaders, and payers to validate clinical practice patterns, procurement dynamics, and access constraints. These conversations informed scenario development and the assessment of tariff-sensitive supply flows.

Secondary sources included peer-reviewed clinical studies, regulatory approvals and guidance documents, product labels, and publicly available company disclosures to triangulate product capabilities, safety profiles, and dosing paradigms. The analysis applied rigorous cross-validation between primary and secondary inputs to ensure consistency and to surface divergences that warranted further investigation. Where appropriate, methodological adjustments accounted for regional regulatory differences and for variations in hospital versus specialty center delivery models.

Data quality checks and expert review cycles were integrated throughout the process to strengthen the robustness of conclusions and to ensure that practical recommendations reflect both clinical realities and operational constraints.

Summative strategic priorities that reconcile innovation, supply continuity, and payer engagement to secure durable access and improved patient outcomes

In conclusion, coagulation factor concentrates occupy a strategic nexus of clinical necessity and technological progress. Recombinant science, extended half-life formulations, and evolving care models present meaningful opportunities to improve patient outcomes and to reduce the burden of infusions, while persistent challenges around plasma supply, manufacturing complexity, and payer scrutiny temper near-term execution risks. Geographic differences in regulatory frameworks and distribution infrastructures further complicate commercialization strategies, requiring regionally tailored approaches.

To succeed, stakeholders must align innovation pipelines with operational investments in supply continuity and evidence generation. By integrating patient-centric services, proactive payer engagement, and resilient procurement strategies, manufacturers and providers can deliver measurable clinical benefits without compromising access. The recommendations in this executive summary provide a roadmap for translating scientific advances into durable clinical and commercial outcomes, preserving the central objective of ensuring timely and effective therapy for patients living with bleeding disorders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of extended half-life factor VIII and IX products to reduce infusion frequency and improve patient adherence
  • 5.2. Increased investment in gene therapy trials targeting hemophilia A and B to offer one-time curative treatment opportunities
  • 5.3. Emergence of biosimilar factor VIII and IX concentrates challenging established branded products on pricing and market access
  • 5.4. Integration of pharmacokinetic-guided personalized dosing platforms to optimize coagulation factor concentrate prophylaxis regimens
  • 5.5. Development of subcutaneous and nonintravenous factor concentrate formulations aimed at improving patient convenience and quality of life
  • 5.6. Expansion of plasma collection networks and digital supply chain solutions to mitigate global shortages of source material
  • 5.7. Application of real-world evidence and registry data to demonstrate long-term safety and efficacy of novel coagulation therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coagulation Factor Concentrates Market, by Product Type

  • 8.1. Plasma Derived
  • 8.2. Recombinant
    • 8.2.1. Extended Half Life
    • 8.2.2. Standard Half Life

9. Coagulation Factor Concentrates Market, by Indication

  • 9.1. Hemophilia A
    • 9.1.1. Mild
    • 9.1.2. Moderate
    • 9.1.3. Severe
  • 9.2. Hemophilia B
    • 9.2.1. Mild
    • 9.2.2. Moderate
    • 9.2.3. Severe
  • 9.3. Von Willebrand Disease
    • 9.3.1. Type I
    • 9.3.2. Type II
    • 9.3.3. Type III

10. Coagulation Factor Concentrates Market, by Formulation

  • 10.1. Liquid
  • 10.2. Lyophilized Powder

11. Coagulation Factor Concentrates Market, by End User

  • 11.1. Hospitals
  • 11.2. Specialty Centers

12. Coagulation Factor Concentrates Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Coagulation Factor Concentrates Market, by Route Of Administration

  • 13.1. Intravenous

14. Coagulation Factor Concentrates Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Coagulation Factor Concentrates Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Coagulation Factor Concentrates Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. CSL Limited
    • 17.3.2. Grifols, S.A.
    • 17.3.3. Octapharma AG
    • 17.3.4. Takeda Pharmaceutical Company Limited
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Novo Nordisk A/S
    • 17.3.7. Sanofi S.A.
    • 17.3.8. Bayer Aktiengesellschaft
    • 17.3.9. LFB S.A.
    • 17.3.10. Kedrion S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. COAGULATION FACTOR CONCENTRATES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. COAGULATION FACTOR CONCENTRATES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COAGULATION FACTOR CONCENTRATES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2025-2032 (USD MILLION)
  • TABLE 293. MID